Hepatitis B reactivation: A possible cause of coronavirus disease 2019 vaccine induced hepatitis DOI Creative Commons
Hsin-Yun Wu, Tung‐Hung Su, Chun‐Jen Liu

и другие.

Journal of the Formosan Medical Association, Год журнала: 2023, Номер 123(1), С. 88 - 97

Опубликована: Июнь 20, 2023

Coronavirus disease 2019 (COVID-19) vaccines were rapidly implemented globally and vaccine-associated immune-related hepatitis was recently reported. We aim to investigate its impact in regions endemic of chronic B (CHB).

Язык: Английский

Manipulating the antioxidative capacity of melanin-like nanoparticles by involving condensation polymerization DOI
Peng Yang, Tianyou Wang, Jianhua Zhang

и другие.

Science China Chemistry, Год журнала: 2023, Номер 66(5), С. 1520 - 1528

Опубликована: Апрель 17, 2023

Язык: Английский

Процитировано

28

Global burden of vaccine‐associated hepatobiliary and gastrointestinal adverse drug reactions, 1967–2023: A comprehensive analysis of the international pharmacovigilance database DOI
Sooji Lee, Kyeongmin Lee, Jaeyu Park

и другие.

Journal of Medical Virology, Год журнала: 2024, Номер 96(7)

Опубликована: Июль 1, 2024

Abstract Although previous studies have focused on hepatobiliary and gastrointestinal adverse drug reactions (ADRs) associated with COVID‐19 vaccines, literature such ADRs other vaccines is limited, particularly a global scale. Therefore, we aimed to investigate the burden of vaccine‐associated identify implicated in these occurrences. This study utilized data from World Health Organization (WHO) international pharmacovigilance database extract reports 1967 2023 (total = 131 255 418). Through reporting counts, reported odds ratios (ROR) 95% confidence interval (CI), information components (IC) IC 0.25 , examined association between 16 incidence across 156 countries. Of 6 842 303 ADRs, 10 786 liver injury, 927 870 symptoms, 2978 pancreas bile duct 96 intra‐abdominal hemorrhage were identified. Most surged after 2020, majority attributed messenger RNA (mRNA) vaccines. Hepatitis A exhibited highest injury (ROR [95% CI]: 10.30 [9.65–10.99]; [IC ]: 3.33 [3.22]), followed by hepatitis B, typhoid, rotavirus. Specifically, ischemic had significant both Ad5‐vectored mRNA Gastrointestinal symptoms all except for tuberculosis rotavirus (11.62 [11.45–11.80]; 3.05 [3.03]) typhoid (11.02 [10.66–11.39]; 3.00 [2.96]). Pancreas (1.99 [1.89–2.09]; 0.90 [0.83]), MMR (measles, mumps, rubella), papillomavirus For hemorrhage, inactivated whole‐virus (3.93 [1.86–8.27]; 1.71 [0.41]) association, (1.81 [1.42–2.29]; 0.77 [0.39]). short time onset, within 1 day, low mortality rate. scale database, occurred emphasizing importance healthcare workers' vigilant monitoring timely management.

Язык: Английский

Процитировано

11

Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study DOI Creative Commons
Xi Xiong, David Tak Wai Lui, Matthew S. H. Chung

и другие.

PLoS Medicine, Год журнала: 2023, Номер 20(7), С. e1004274 - e1004274

Опубликована: Июль 24, 2023

Background The risk of incident diabetes following Coronavirus Disease 2019 (COVID-19) vaccination remains to be elucidated. Also, it is unclear whether the after Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) infection modified by status or differs SARS-CoV-2 variants. We evaluated incidence mRNA (BNT162b2), inactivated (CoronaVac) COVID-19 vaccines, and infection. Methods findings In this population-based cohort study, individuals without known were identified from an electronic health database in Hong Kong. first included people who received ≥1 dose vaccine those did not receive any vaccines up September 2021. second consisted confirmed patients never infected March 2022. Both cohorts followed until August 15, A total 325,715 recipients (CoronaVac: 167,337; BNT162b2: 158,378) 145,199 1:1 matched their respective controls using propensity score for various baseline characteristics. also adjusted previous when estimating conditional probability receiving vaccinations, contracting Hazard ratios (HRs) 95% confidence intervals (CIs) estimated Cox regression models. cohort, we 5,760 4,411 cases CoronaVac BNT162b2 respectively. Upon a median follow-up 384 386 days, there was no evidence increased risks 9.08 versus 9.10 per 100,000 person-days, HR = 0.998 [95% CI 0.962 1.035]; 7.41 8.58, 0.862 [0.828 0.897]), regardless type. observed 2,109 164 associated with significantly higher (9.04 7.38, 1.225 [1.150 1.305])—mainly type diabetes—regardless predominant circulating variants, albeit lower Omicron variants (p interaction 0.009). number needed harm at 6 months 406 1 additional case. Subgroup analysis revealed among fully vaccinated survivors. Main limitations our study possible misclassification bias as through diagnostic coding residual confounders due its observational nature. Conclusions There vaccination. infection, mainly diabetes. excess lower, but still statistically significant, Fully might protected

Язык: Английский

Процитировано

22

Developing mRNA Nanomedicines with Advanced Targeting Functions DOI Creative Commons
Ji Wang, Lijun Cai, Ning Li

и другие.

Nano-Micro Letters, Год журнала: 2025, Номер 17(1)

Опубликована: Фев. 21, 2025

The emerging messenger RNA (mRNA) nanomedicines have sprung up for disease treatment. Developing targeted mRNA has become a thrilling research hotspot in recent years, as they can be precisely delivered to specific organs or tissues enhance efficiency and avoid side effects. Herein, we give comprehensive review on the latest progress of with targeting functions. its carriers are first described detail. Then, mechanisms passive targeting, endogenous active outlined, focus various biological barriers that may encounter during vivo delivery. Next, emphasis is placed summarizing mRNA-based organ-targeting strategies. Lastly, advantages challenges clinical translation mentioned. This expected inspire researchers this field drive further development technology.

Язык: Английский

Процитировано

1

SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease DOI Creative Commons
Hendrik Luxenburger, Robert Thimme

Gut, Год журнала: 2023, Номер 72(9), С. 1783 - 1794

Опубликована: Июнь 14, 2023

SARS-CoV-2 infection may affect the liver in healthy individuals but also influences course of COVID-19 patients with chronic disease (CLD). As described individuals, a strong SARS-CoV-2-specific adaptive immune response is important for outcome COVID-19, however, knowledge on CLD limited.Here, we review clinical and immunological features CLD. Acute injury occurs many cases be induced by multiple factors, such as cytokines, direct viral or toxic effects drugs. In CLD, have more severe promote decompensation particularly cirrhosis. Compared responses impaired after both, natural vaccination improves at least partially booster vaccination.Following vaccination, rare acute vaccine-induced development autoimmune-like hepatitis been reported. However, concomitant elevation enzymes reversible under steroid treatment.

Язык: Английский

Процитировано

16

Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics DOI Creative Commons
Sarp Uzun, Carl Zinner, Amke C. Beenen

и другие.

Journal of Hepatology, Год журнала: 2023, Номер 79(3), С. 666 - 676

Опубликована: Июнь 7, 2023

Liver injury after COVID-19 vaccination is very rare and shows clinical histomorphological similarities with autoimmune hepatitis (AIH). Little known about the pathophysiology of vaccine-induced liver (VILI) its relationship to AIH. Therefore, we compared VILI AIH.Formalin-fixed paraffin-embedded biopsy samples from patients (n = 6) an initial diagnosis AIH 9) were included. Both cohorts by evaluation, whole-transcriptome spatial transcriptome sequencing, multiplex immunofluorescence, immune repertoire sequencing.Histomorphology was similar in both but showed more pronounced centrilobular necrosis VILI. Gene expression profiling that mitochondrial metabolism oxidative stress-related pathways interferon response less enriched Multiplex analysis revealed inflammation dominated CD8+ effector T cells, drug-induced autoimmune-like hepatitis. In contrast, a dominance CD4+ cells CD79a+ B plasma cells. T-cell receptor (TCR) B-cell sequencing cell clones dominant than addition, many detected also found blood. Interestingly, TCR beta chain Ig heavy variable-joining gene usage further TRBV6-1, TRBV5-1, TRBV7-6, IgHV1-24 genes are used differently AIH.Our analyses support SARS-CoV-2 related distinct differences histomorphology, pathway activation, cellular infiltrates, usage. may be separate entity, which closely hepatitis.Little (VILI). Our shares some hepatitis, has such as increased activation metabolic pathways, prominent infiltrate, oligoclonal response. findings suggest disease entity. there good chance will recover completely not develop long-term

Язык: Английский

Процитировано

15

Glycyrrhizic acid restores the downregulated hepatic ACE2 signaling in the attenuation of mouse steatohepatitis DOI

Longyue Zhou,

Shankang Chen,

Yuanyi Wei

и другие.

European Journal of Pharmacology, Год журнала: 2024, Номер 967, С. 176365 - 176365

Опубликована: Фев. 3, 2024

Язык: Английский

Процитировано

6

Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients DOI Creative Commons
Carlos King Ho Wong, David Tak Wai Lui, Xi Xiong

и другие.

BMC Medicine, Год журнала: 2022, Номер 20(1)

Опубликована: Окт. 14, 2022

Abstract Background In view of accumulating case reports thyroid dysfunction following COVID-19 vaccination, we evaluated the risks incident inactivated (CoronaVac) and mRNA (BNT162b2) vaccines using a population-based dataset. Methods We identified people who received vaccination between 23 February 30 September 2021 from electronic health database in Hong Kong, linked to records. Thyroid encompassed anti-thyroid drug (ATD)/levothyroxine (LT4) initiation, biochemical picture hyperthyroidism/hypothyroidism, Graves’ disease (GD), thyroiditis. A self-controlled series design was used estimate incidence rate ratio (IRR) 56-day post-vaccination period compared baseline (non-exposure period) conditional Poisson regression. Results total 2,288,239 at least one dose (57.8% BNT162b2 recipients 42.2% CoronaVac recipients). 94.3% 92.2% second dose. Following first there no increase ATD initiation (BNT162b2: IRR 0.864, 95% CI 0.670–1.114; CoronaVac: 0.707, 0.549–0.912), LT4 0.911, 0.716–1.159; 0.778, 0.618–0.981), hyperthyroidism 0.872, 0.744–1.023; 0.830, 0.713–0.967) or hypothyroidism 1.002, 0.838–1.199; 0.963, 0.807–1.149), GD, Similarly, 0.972, 0.770–1.227; 0.879, 95%CI 0.693–1.116), 1.019, 0.833–1.246; 0.768, 0.613–0.962), 1.039, 0.899–1.201; 0.786–1.055), 0.935, 0.794–1.102; 0.945, 0.799–1.119), Age- sex-specific subgroup sensitivity analyses showed consistent neutral associations both types vaccines. Conclusions Our study evidence vaccine-related with CoronaVac.

Язык: Английский

Процитировано

22

COVID-19 Vaccination in Patients with Chronic Liver Disease DOI Creative Commons
Georgios Schinas,

Eleni Polyzou,

Fevronia Mitropetrou

и другие.

Viruses, Год журнала: 2022, Номер 14(12), С. 2778 - 2778

Опубликована: Дек. 13, 2022

Vaccination against SARS-CoV-2 has become a central public health issue, primarily for vulnerable populations such as individuals with Chronic Liver Disease (CLD). Increased COVID-19-related mortality and disease severity been noted in this subgroup of patients. Severe COVID-19 tends to further deregulate liver function patients chronic failure or cirrhosis even reactivate hepatitis people living HBV HCV. In addition, impaired hepatic leads several limitations possible therapeutic interventions. dysregulation, along the underlying cirrhosis-associated immune dysfunction (CAID), decreased response vaccination that, turn, may result reduced efficacy rates lowered lasting protection. According current guidelines, timely frequent booster shot administration are deemed necessary context. Vaccination-related adverse events mostly mild nature similar those reported general population, whereas incidence injury following is relatively rare. We aimed review available evidence recommendations associated disease, provide insight issues future directions.

Язык: Английский

Процитировано

22

Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study DOI Creative Commons
Vincent Ka Chun Yan, Franco Wing Tak Cheng, Celine Sze Ling Chui

и другие.

Emerging Microbes & Infections, Год журнала: 2023, Номер 12(1)

Опубликована: Март 5, 2023

Severe COVID-19 appears to be disproportionately more common in children and adolescents since the emergence of Omicron. More evidence regarding vaccine effectiveness (VE) is urgently needed assist policymakers making decisions minimize hesitancy among public. This was a case-control study pediatric population using data extracted from electronic health records database Hong Kong. Individuals aged 3-17 with confirmed by polymerase chain reaction were included study. Each case matched up 10 controls based on age, gender, index date (within 3 calendar days). The VE BNT162b2 CoronaVac preventing COVID-19, hospitalizations, severe outcomes estimated conditional logistic regression adjusted patients' comorbidities medication history during outbreak January August 2022. A total 36,434 cases, 2231 COVID-19-related 1918 cases 109,004, 21,788, 18,823 controls, respectively. Compared unvaccinated group, three doses or associated reduced risk infection [VE: BNT162b2: 56.0% (95% CI: 49.6-61.6), CoronaVac: 39.4% 25.6-50.6)], hospitalization 58.9% 36.1-73.6), 51.7% (11.6-73.6)], 60.2% 33.7-76.1), 42.2% -6.2-68.6)]. Our findings showed that effective Omicron-dominant pandemic, which further enhanced after booster dose.

Язык: Английский

Процитировано

12